Litigation Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)
✉ Email this page to a colleague
Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)
Docket | ⤷ Try a Trial | Date Filed | 2017-06-30 |
Court | District Court, N.D. West Virginia | Date Terminated | 2020-06-22 |
Cause | 35:271 Patent Infringement | Assigned To | Irene Patricia Murphy Keeley |
Jury Demand | None | Referred To | James P. Mazzone |
Parties | BIOGEN MA, INC. | ||
Patents | 10,029,015; 6,509,376; 6,926,907; 7,320,999; 7,619,001; 7,803,840; 8,013,002; 8,399,514; 8,759,393; 9,018,017; 9,024,096 | ||
Attorneys | Sanya Sukduang | ||
Firms | Schrader Companion Duff & Law, PLLC | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Biogen International GMBH v. Mylan Pharmaceuticals Inc.
Biologic Drugs cited in Biogen International GMBH v. Mylan Pharmaceuticals Inc.
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2017-06-30 | 1 | Complaint | “the ‘999 patent”), 7,619,001 (“the ‘001 patent”), 7,803,840 (“the ‘840 patent”), 8,759,393 (“the ‘393…- 376 Patent, # 2 Exhibit B - 999 Patent, # 3 Exhibit C - 001 Patent, # 4 Exhibit D - 840 Patent, # 5 …is an action for patent infringement of U.S. Patent Nos. 6,509,376 (“the ‘376 patent”), 7,320,999 (“the…393 patent”) and 8,399,514 (“the ‘514 patent”) arising under the patent laws of the United States, Title…5 Exhibit E - 393 Patent, # 6 Exhibit F - 514 Patent, # 7 Civil Cover Sheet)(lmm) (Entered: 06/30/2017 | External link to document |
2018-10-12 | 142 | Status Report | infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ’999 patent”), 7,619,001 … (“the ’001 patent”), 7,803,840 (“the ’840 patent”), 8,759,393 (“the ’393 patent”) and 8,399,514 … the patents-in-suit. The ’393 patent has expired. It is Mylan’s position that this patent should be…partes review (“IPR”) of Biogen’s ’514 patent. Biogen’s Patent Owner’s Preliminary Response is due on…for regulatory patent term extension (“PTE”) on the ’376, ’999, ’001, and ’840 patents. Under the relevant | External link to document |
2019-02-05 | 196 | Stipulation and Order | regarding U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ’999 patent”), 7,803,840 (…affirmative defenses related to U.S. Patent Nos. 6,509,376; 7,320,999; 7,803,840; and 8,759,393. The parties…regarding the ’376 patent, the ’999 patent, the ’840 patent, and the ’393 patent; (iii) Defendants…regarding the ’376 patent, the ’999 patent, the ’840 patent, and the ’393 patent; and (iv…counterclaims regarding ’376 patent, the ’999 patent, the ’840 patent, and the ’393 patent. It is further | External link to document |
2019-10-08 | 288 | Order | Parties to this patent infringement case involving U.S. Patent Nos. 8,399,514 (“the °514 patent”) and 7,619,001… 15-16 of the °514 patent and claims 1-3, 6-9, 12-19, and 22-24 of the *001 patent under 35 U.S.C. § 271…and 15-16 of the 514 patent and claims 1-3, 6-9, 12-19, and 22-24 of the °001 patent are not invalid and…7,619,001 (‘the 001 patent”); WHEREAS the Parties wish to narrow the issues in this litigation; WHEREAS…that it will not assert claims 17-19 of the 514 patent against Mylan (see ECF 102); THEREFORE, IT IS | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |